Wentz Steps Down From Immunosyn Board
Wentz said he is increasing his focus on his humanitarian and charitable endeavors, having recently founded the Wentz Medical Centre and Laboratory in Uganda and the Wentz Medical Centre in Cambodia to serve children in those countries orphaned by diseases such as malaria and HIV.
Myron Wentz said, "I continue my interest in Immunosyn's efforts through Argyll Biotechnologies, LLC to seek approvals and commercialization of SF-1019. I plan to use the resources available to me to assist in any appropriate way so that SF-1019 can eventually be used at Sanoviv Medical Institute."
Wentz founded Sanoviv and, in June of 2007 was a recipient of the Albert Einstein Award for Outstanding Achievement in the Life Sciences.
La Jolla, California-headquartered Immunosyn plans to market and distribute therapeutics. The company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers.
Argyll Biotechnologies has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the U.S. and Europe.
The company said that its research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as multiple sclerosis, neurological disorders such as chronic inflammatory demyelinating polyneuropathy and reflex sympathetic dystrophy syndrome and complications from diabetic mellitus such as diabetic neuropathy and diabetic ulcers.
FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .
Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .
Copyright(C)2009 by financialwire.net, Inc. All rights reserved.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
